EPR: 2022 biopharma trend predictions roundtable

Scroll Down

From supply challenges surrounding COVID-19 to regulatory changes and innovations, the year 2022 is set to be an interesting year for biopharma manufacturing companies around the world.

Here, Bill Vincent, Founder and Executive Chairman at Genezen provides his insights into the top biopharma trends we can expect to see in 2022. He also highlights the impact of regulatory changes on serum use for cell growth and the potential of stable producer cell lines throughout cell and gene therapy manufacturing.

Read the full article: Key challenges for biopharmaceutical manufacturing 2022

You may also be interested in...

4 factors driving the trend towards…

The cell and gene therapy (C&GT) space is expanding rapidly. With...

Read more

Genezen appoints Chief Commercial Officer to…

  Genezen, a cell and gene therapy Contract Development and Manufacturing...

Read more

Downstream Process Development for Lentiviral Vectors…

Lentiviral vectors (LVV) are commonly used as an efficient and safe...

Read more

Stable cell lines vs transient transfection…

The aim of upstream processing in viral vector development and manufacturing...

Read more